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We present trends in incidence, early treatment and survival of Chronic Lymphocytic
Leukaemia (CLL) between 1989 and 2008, based on population-based data from the Nether-
lands Cancer Registry.
Incidence rates were stable at 5.1 per 100,000 person-years for males, but increased from
2.3 to 2.5 for females, especially for females aged 50–64 years (from 3.6 to 4.3).
Patients were less likely to receive chemotherapy within six months, i.e. from 29% to 24%
among males and from 25% to 21% among females. Five-year relative survival increased
from 61% in 1989–1993 to 70% 2004–2008 for males, and from 71% to 76% for females.
The relative excess risk of dying decreased in time to 0.7 (males) and 0.9 (females) in
2004–2008, reference 1989–1993, and increased with age to 2.9 (males) and 1.8 (females)
in patients aged 75–94 years, reference 30–64 years.
The increasing incidence among females aged 50–64 coincided with the introduction of
mass screening for breast cancer, which resulted in a large group of women under
increased surveillance and possibly led to increased detection of CLL. The increase in sur-
vival might be underestimated due to possible decreased or delayed registration of indolent
cases and the retroactive effect of the introduction of new therapies.
 2011 Elsevier Ltd. Open access under the Elsevier OA license. 1. Introduction
Chronic Lymphocytic Leukaemia (CLL) is the most common
type of leukaemia in adults in western countries, both in
terms of incidence and prevalence.1 Median survival time issive Cancer Centre South
31 40 2971610.
n den Broek).
he Elsevier OA license. 10 years, ranging from months when the disease behaves
aggressively, to decades for patients with an indolent course
of the disease.2
The rising life expectancy of the Western population will
lead to an increased number of patients with cancers that(IKZ), Eindhoven Cancer Registry, P.O. Box 231, 5600 AE Eindhoven,
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being 22 per 100,000 per year among people older than 65).3
Furthermore, the incidence of CLL has been reported to be
increasing among younger patients.4 These two trends will
lead to an increase in the prevalence.
Over the last decades, diagnostic tools have been refined,
i.e. the use of flow cytometry to discriminate CLL from other
lymphoproliferative disorders was gradually implemented
since 1989,5 leading to earlier detection and better discrimina-
tion between ‘true’ CLL and its mild precursor Monoclonal
B-Cell Lymphocytosis (MBL).6
Treatment options for patients with advanced disease
have also changed. First, there was a breakthrough with the
introduction of purine analogues such as fludarabine in the
1980s, followed by the introduction of monoclonal antibodies
at the beginning of this century.7,8 Although response rates
improved, randomised clinical trials (RCTs) comparing these
newer treatments regimens failed to show improved overall
survival, until recently. In 2010, a phase III study showed
improvement of survival (three-year survival 87% versus
82%) after addition of a monoclonal antibody.9
Survival of the entire group of CLL patients might have al-
ready improved over the years coinciding the aforementioned
developments, more therapeutic awareness, better support-
ive care and early detection. We therefore describe both
long-term and recent trends in incidence, treatment and sur-
vival in a Western European, haematologically well-served
country, using the Netherlands Cancer Registry.
2. Patients and methods
The nationwide Netherlands Cancer Registry (NCR) was
started in 1989 and is maintained and hosted by the regional
cancer registries at eight regional Comprehensive Cancer
Centres.10 The NCR is based on notification of all newly diag-
nosed malignancies in the Netherlands by the automated
pathological archive (PALGA), supplemented by notifications
from the national registry of hospital discharge, various hae-
matology and clinical chemistry laboratories and radiother-
apy institutions. Information on patient characteristics such
as gender and date of birth, tumour characteristics such as
date of diagnosis and morphology (ICD-O-3),11 and primary
treatment are obtained routinely from the medical records
6–12 months after diagnosis.
Information on date of death was actively obtained from
the municipal registries and from the database of deceased
persons of the Central Bureau for Genealogy and the munici-
pal civil registries (GBA) (date of last follow-up: 1st January
2010). Survival time was calculated as the time from diagnosis
to death or to 1st January 2010.
For the present study, all patients diagnosed with CLL
(ICD-O-2 codes 9592 and 9803, ICD-O-2/ICD-O-3 codes 9670,
9800, 9820, and 9823) in the period 1989–2008, aged 30 and over
and recorded in the Netherlands Cancer Registry (NCR) were
included (N = 13,419). Age at diagnosis was divided into three
groups (30–64, 65–74, and P75 years). Incidence rates were
also calculated for the populations 30–49 and 50–64 years.
The study period was divided into four categories: 1989–1993,
1994–1998, 1999–2003, and 2004–2008. For the period1989–1994 survival data from only five out of eight regional
cancer registries was available, but were considered represen-
tative for the whole of the Netherlands. Patients older than
95 years at diagnosis were excluded from survival analysis
(since follow-up is less reliable for this subgroup).
Annual incidence rates for the period 1989–2008 were cal-
culated per 100,000 person-years, using the annual mid-year
population size as obtained from statistics Netherlands.
Rates were age-standardised to the European standard pop-
ulation (European Standardised Rates (ESR)). Incidence rates
were also calculated according to gender and age group.
Trends in incidence were evaluated by calculating the esti-
mated annual percentage change (EAPC) and the corre-
sponding 95% confidence interval (95% CI). To calculate
this, a regression line was fitted to the natural logarithm of
the rates, using the calendar year as regressor variable (i.e.
y = ax + b where y = ln (rate) and x = calendar year, then
EAPC = 100 * (ea ) 1)).
Treatment was described as the proportion patients who
received no therapy, chemotherapy (whether or not combined
with other kinds of therapy) or other therapy in the first
6 months after diagnosis. Detailed information on type of sys-
temic therapy was not available until 2007.
Traditional cohort-based analysis was applied to calculate
relative survival rates for patients diagnosed during
1989–2008. Since follow-up was available until January 2010,
10-year relative survival of patients diagnosed in the period
1999–2003 and the 5- and 10-year relative survival for patients
diagnosed in the period 2004–2008 could not be calculated
with the cohort-based method. To estimate these relative sur-
vival rates we used period-based relative survival analysis.12
Multivariate relative survival analyses, using Poisson regres-
sion modelling,13 were carried out to estimate relative excess
risk (RER) of dying adjusted for the follow-up interval and age
category. We stratified for gender because effect modification
was observed. SAS software (SAS system 9.2, SAS Institute,
Cary, NC) was used to perform the statistical analyses.
3. Results
The distribution over the age categories was stable in males
(P = 0.09), with 36% aged 30–64, 34% aged 65–74 and 30%
aged 75 or older. In females a shift towards the youngest
age category was seen, from 24% aged 30–64 in 1989–1993 to
32% in 2003–2008 (P = 0.00) (Table 1).
For all age groups together, the overall incidence rate
(3.8 per 100,000 person years) and the incidence rate for males
(5.1 per 100,000 person-years) were stable, whereas among fe-
males it increased slightly from 2.3 in 1989 to 2.5 per 100,000
person-years in 2008 (EAPC = 0.8%; 95% CI: 0.1–1.6).
In the population 30–64 years, the incidence rate increased
from 3.7 to 3.9 per 100,000 person-years (EAPC = 0.6%; 95% CI:
0.1–1.1) for males and from 1.6 to 2.1 per 100,000 person-years
(EAPC = 2.2%; 95% CI: 0.7–3.7) for females (results not shown).
Additional analysis of the populations aged 30–49 and 50–64
revealed that the increase in incidence for females was
entirely attributable to an increase in the population aged
50–64 years, where the incidence rose from 3.6 to 4.3 per
100,000 person-years (EAPC = 2.1%; 95% CI: 0.4–3.8) (Fig. 1a).
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Fig. 1a – Three-year moving average of age-standardised incidence rates (ESR) of CLL in the Netherlands 1989–2008 according
to gender, for patients aged 30–49 years and 50–64 years at diagnosis.
Table 1 – Age, sex and subclassification distribution of CLL patients in the Netherlands, 1989–2008.
Males Females
1989–1993
N (%)
1994–1998
N (%)
1999–2003
N (%)
2004–2009
N (%)
1989–1993
N (%)
1994–1998
N (%)
1999–2003
N (%)
2004–2009
N (%)
Age
30–64 567
(35%)
690
(35%)
791
(38%)
850
(37%)
279
(24%)
311
(24%)
476
(32%)
495
(32%)
65–74 541
(33%)
705
(36%)
707
(34%)
729
(32%)
371
(32%)
426
(34%)
398
(27%)
415
(27%)
P75 507
(31%)
565
(29%)
606
(29%)
695
(31%)
526
(45%)
533
(42%)
608
(41%)
628
(41%)
Morphology code
9592 89
(6%)
59
(3%)
30
(1%)
0
(0%)
74
(6%)
47
(4%)
18
(1%)
0
(0%)
9670 114
(7%)
242
(12%)
339
(16%)
424
(19%)
90
(8%)
151
(12%)
279
(19%)
377
(25%)
9800 30
(2%)
26
(1%)
10
(<1%)
0
(0%)
18
(2%)
29
(2%)
14
(1%)
3
(<1%)
9803 4
(<1%)
3
(<1%)
2
(<1%)
0
(0%)
2
(<1%)
2
(<1%)
0
(<1%)
0
(<1%)
9820 2
(<1%)
3
(<1%)
10
(<1%)
3
(<1%)
4
(<1%)
1
(<1%)
5
(<1%)
1
(<1%)
9823 1376
(85%)
1627
(83%)
1713
(81%)
1847
(81%)
988
(84%)
1040
(82%)
1166
(79%)
1157
(75%)
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around 24 and 12 per 100,000 person-years for males and fe-
males, respectively. In the population aged 75 and older the
rates were stable around 36 and 19 per 100,000 person-years,
respectively. (Fig. 1b)
The proportion of newly diagnosed patients treated with
chemotherapy within 6 months after diagnosis decreasedfrom 29% to 24% for males and from 25% to 21% for females,
remaining higher for males in all age groups (results not
shown) and periods (Fig. 2).
For males, one-year survival increased from 86% in
1989–1993 to 91% 2004–2008 and three-year survival from
73% to 81%. Five-year survival went from 61% to 70%, 10-year
survival was stable around 45%. For females, one-year
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Fig. 1b – Three-year moving average of age-standardised incidence rates (ESR) of CLL in the Netherlands 1989–2008 according
to gender, for patients aged 65–74 years and 75+ years at diagnosis.
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Fig. 2 – Proportion of patients treated with chemotherapy within 6 months of diagnosis, in the Netherlands, according to age,
gender and period.
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creased from 81% to 85%, five-year survival went from 71%
to 76% and 10-year survival from 51% to 59%. Five- and 10-
year survival rates for 2004–2008 were estimated with period
analysis. Relative survival decreased with rising age at diag-
nosis, but was higher for females than for males at almost
all times and in all age categories (Table 2).
The relative excess risk of dying decreased in time to 0.7
and 0.9 in 2004–2008, males and females respectively, refer-
ence 1989–1993, and increased with age to 2.9 and 1.8 in pa-
tients aged 75–94 years, males and females, respectively,
reference 30–64 years (Table 3).4. Discussion
In this study with unselected data on CLL diagnosed in the en-
tire Netherlands over a period of 20 years, we saw an increase
in incidence for females aged 50–64 years (from 3.6 to 4.3 per
100,000 person-years). The proportion of patients receiving
chemotherapy within 6 months decreased and survival rates
increased modestly.
The overall age standardised incidence rate of 3.8 per
100,000 was in accordance with European data.14 A paper on
trends in incidence in the USA from 1987 to 2001 also reported
a stable incidence rate.15 In Denmark an increase in incidence
Table 2 – Relative survival rates (standard error) for CLL patients according to gender and period of diagnosis, the Netherlands.
Age group Survival rate
after year
1989–1993 1994–1998 1999–2003 2004–2008
Males
All 1 86.4 (1.1) 88.0 (0.9) 89.7 (0.8) 91.1 (0.7)
3 72.8 (1.5) 77.0 (1.2) 78.4 (1.1) 80.7 (1.1)
5 60.6 (1.8) 65.5 (1.4) 67.8 (1.3) 69.5* (1.3)
10 43.5 (2.0) 43.4 (1.6) 47.5* (1.8) 44.9* (1.6)
30–64 1 92.9 (1.2) 92.1 (1.1) 96.5 (0.7) 95.2 (0.8)
3 83.2 (1.9) 84.6 (1.5) 88.6 (1.3) 89.1 (1.3)
5 71.4 (2.3) 76.2 (1.8) 80.1 (1.6) 79.5* (1.5)
10 51.2 (2.6) 54.3 (2.2) 59.6* (2.4) 55.5* (2.0)
65–74 1 87.5 (1.8) 90.6 (1.3) 90.7 (1.3) 91.8 (1.2)
3 70.6 (2.6) 78.5 (2.0) 79.8 (1.9) 79.9 (1.9)
5 56.1 (3.0) 63.5 (2.4) 66.0 (2.2) 65.5* (2.1)
10 43.2 (3.7) 36.0 (2.6) 44.0* (3.1) 37.0* (2.5)
75–95 1 76.6 (2.6) 78.7 (2.2) 78.4 (2.1) 84.6 (1.8)
3 61.1 (3.6) 63.2 (3.0) 60.8 (2.8) 69.9 (2.8)
5 50.8 (4.3) 51.5 (3.6) 50.0 (3.2) 58.8* (3.3)
10 30.8 (6.1) 36.5 (5.2) 31.8* (5.5) 36.4* (5.0)
Females
All 1 89.6 (1.2) 88.6 (1.1) 90.7 (0.9) 91.4 (0.8)
3 80.6 (1.6) 80.2 (1.4) 81.5 (1.3) 84.9 (1.2)
5 71.4 (1.9) 72.7 (1.7) 73.5 (1.5) 76.3* (1.5)
10 51.2 (2.3) 55.3 (2.1) 55.9* (2.2) 58.5* (1.9)
30–64 1 97.1 (1.2) 95.5 (1.3) 97.3 (0.8) 98.0 (0.7)
3 90.2 (2.1) 92.2 (1.7) 90.4 (1.5) 92.9 (1.4)
5 82.3 (2.7) 86.2 (2.2) 83.5 (1.9) 85.2* (1.8)
10 57.6 (3.5) 72.0 (2.9) 66.8* (3.1) 71.3* (2.4)
65–74 1 95.8 (1.4) 95.1 (1.2) 92.0 (1.5) 95.8 (1.1)
3 89.7 (2.2) 85.0 (2.1) 82.3 (2.2) 88.6 (2.0)
5 78.8 (2.9) 75.5 (2.6) 75.9 (2.6) 80.8* (2.4)
10 56.9 (3.8) 56.9 (3.3) 56.8* (3.4) 58.7* (3.3)
75–95 1 80.6 (2.3) 78.9 (2.1) 84.1 (1.8) 82.6 (1.8)
3 67.8 (3.1) 68.0 (2.8) 73.1 (2.5) 75.0 (2.6)
5 58.9 (3.7) 61.1 (3.4) 62.5 (3.0) 64.9* (2.9)
10 44.5 (5.4) 40.0 (4.6) 45.0* (5.2) 45.1* (4.4)
* Estimation based on period-analysis.
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data before 1989 out of consideration, we see trends similar
to our findings.
For patients younger than 65 years, we saw an increase in
incidence, that was most pronounced among middle-aged
women (50–65 years), which might be explained by higher
detection levels following the gradual implementation of the
breast cancer screening programme in the Netherlands start-
ing in 1990. This resulted in an increase in breast cancer sur-
vivors,17 who undergo frequent medical check ups that could
expose CLL coincidentally. The decrease in incidence among
females aged 50–64 between 2004 and 2008 is another indica-
tion for increased detection among this group. Because of
CLL’s long subclinical phase, detecting all patients at a certain
period at a subclinical phase, will cause an increase in inci-
dence, which will be followed by a decline, as all the cases
that would be detected as the patient presented with symp-
toms are already diagnosed.The higher use of health care services among middle-aged
women,18 could also have led to increased detection in this
group.
Some of the fluctuations in the incidence rates in males
showed similarities with fluctuations in the incidence of pros-
tate cancer,19 leading us to assume that increased detection
among cancer survivors might be of influence here too.
Men received systemic therapy more often than women in
the first half year after diagnosis, suggesting that women
were diagnosed with early-stage disease more often, as was
seen in previous studies.20
A decreasing proportion of patients was treated within
6 months after diagnosis. Physicians may have become more
hesitant about systemic therapy. International guidelines for
indications for treatment have not changed essentially, how-
ever there was a trend towards the stronger in discourage-
ment of treatment of indolent patients without active
disease.21–23 Another explanation is that diagnoses may have
Table 3 – Relative excess risk of dying for CLL patients in the
Netherlands.
Variable RER 95% CI
Males
Period of diagnosis
1989–1993 1
1994–1998 0.8* 0.7–1.0
1999–2003 0.8* 0.7–0.9
2004–2008 0.7* 0.6–0.8
Age group (years)
30–64 1
65–74 1.8* 1.6–2.0
75–94 2.9* 2.6–3.3
Females
Period of diagnosis
1989–1993 1
1994–1998 0.8 0.5–1.3
1999–2003 0.6 0.4–1.1
2004–2008 0.9 0.4–1.8
Age group (years)
30–64 1
65–74 1.3 0.8–2.1
75–94 1.8* 1.1–3.0
Multivariate relative survival analyses, using Poisson regression
modelling, to estimate relative excess risk (RER) of dying adjusted
for follow-up interval.
* P < 0.05.
894 E U R O P E A N J O U R N A L O F C A N C E R 4 8 ( 2 0 1 2 ) 8 8 9 –8 9 5been set earlier and at a more indolent stage. This is consis-
tent with the shift towards younger age at diagnosis we
observed.
A stage shift towards earlier stages could also explain the
increasing survival rates, in the absence of life-prolonging
therapies. A decreasing trend was visible in excess risk of
dying; however not statistically significant for females,
probably due to the small number of patients.
Till recently, few trials showed improvement in survival as
a result of anti-cancer treatment.24 The improvement in sur-
vival in our study might have resulted from earlier detection
and/or better supportive care rather than improved systemic
treatment.
In most age categories and periods, relative survival rates
appeared to be higher for females than for males. In other
studies this was suggested to be attributable to better longev-
ity of women.20 However, our relative survival rates were age
and gender-adjusted, so there should be another reason. As
mentioned earlier, men might be diagnosed more often with
advanced stage disease than women or they may suffer more
comorbidities. A first analysis of the comorbidities in a subset
of the population showed that male CLL patients did not pres-
ent more often with comorbidities in general, but they did suf-
fer more often from life-threatening cardiovascular diseases.
The difference in survival between males and females de-
creased. In the USA and Sweden higher relative survival rates
for females and trends toward smaller gender differences
were also observed.4,25 In Barcelona, stable survival rates for
females and increased survival rates for males were observed,
as well as stable rates for patients with Binet stage A andincreased rates in patients with stage B/C.2 If men are diag-
nosed more often in a later stage, this could clarify why they
benefit more from developments in treatment than women. It
also explains why the presumed higher detection rates for
middle-aged women did not result in marked improvement
of survival.
The significantly higher relative excess risk of dying of old-
er patients was also in line with the American and Swedish
data.4,25
We should consider several limitations of this analysis: the
basis for the diagnostic criteria for CLL changed from absolute
lymphocyte count (ALC) towards B-cell count. A single centre
study showed that 42% of the patients who would be classi-
fied as having Rai stage 0 CLL according to their ALC, would
be classified as having MBL using B-cell count,26 i.e. the pro-
portion of patients with a good prognosis decreased. However,
since the guidelines did not recommend the use of B-cell
count until 2008,27 the influence on the data presented in this
article was probably limited.
Furthermore, cancer registries could always rely on
pathology reports to signal new CLL cases, but the introduc-
tion of flow cytometry changed this. Before, a bone marrow
or lymph node biopsy was performed to confirm the primary
diagnosis of CLL. Currently, these biopsies are only indicated
in case of doubt of the diagnosis, when transformation to
Richter’s disease is suspected or in case of cytopenia. As a re-
sult, a substantial number of CLL cases will not be recorded in
the cancer registries, causing underestimation of the inci-
dence28 and stressing the necessity for cancer registries to
adapt their approach to CLL registration. If underreporting
concerns mainly indolent cases, then underestimation of
the survival rates would follow.
Third, for the present study, ICD-O-2 codes 9592 and 9803,
ICD-O-2/ICD-O-3 codes 9670, 9800, 9820 and 9823 were used
to select patients with CLL/SLL. Not all codes indicate CLL or
SLL specifically. 9592, 9800, 9803 and 9820 are more generic.
The NCR has reviewed all patients that were recorded after
1999 with generic codes, and replaced these codes by more
specific codes if the source provided sufficient information.
It appeared that most cases concerned CLL, hence the cases
that were not recoded (either because the diagnoses was be-
fore 2000 or the source did not provide enough details) were
classified as CLL/SLL.29 To discard cases with these non-spe-
cific codes that are probably not CLL patients, we excluded
patients that were younger than 30 at time of diagnosis
(N = 27).
Finally, since the time-to-therapy can be many years for
CLL patients, the introduction of new therapies has a retroac-
tive effect; previously diagnosed patients also benefit from it
upon disease progression, resulting in a less steep increase
of survival rates.
In conclusion, the gender differences in the incidence of
CLL remained but became smaller. The incidence rate for fe-
males increased towards the stable incidence rate for males,
probably due to increased detection rates in women. The
modest increase in survival is possibly underestimated as a
result of underregistration of recently diagnosed indolent
cases and the retroactive effect of the introduction of new
therapies.
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